

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Ulrich Laemmli
U.S. Serial No.: Not Yet Known
Filed : Herewith
For : MODULATION OF CHROMOSOME FUNCTION BY
CHROMATIN REMODELING AGENTS

1185 Avenue of the Americas
New York, New York 10036
June 26, 2001

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

PRELIMINARY AMENDMENT

Applicants request that the following amendments be made in the
above-identified application.

In the Specification

Page 1, after the title please insert the following paragraph:

--This application claims priority of U.S. Provisional
Application No. 60/213,931, filed June 26, 2000, the
contents of which are hereby incorporated by reference
into the present disclosure.--

Ulrich Laemmli
Serial No.: Not Yet Known
Filed: Herewith
Page 2

In the Claims:

Please cancel claims 40-76 without prejudice to applicants' right to pursue the subject matter of these claims in a subsequent application.

Please amend claims 9, 11, 15, 16, 20 and 21. The text of the claims as amended follows:

- 9.(amended) Process according to claim 1, wherein the CRE is cis-acting with respect to said other DNA element(s), in either a local or long-range manner.--
- 11.(amended) Process according to claim 1 wherein the CRE is trans-acting in that the other DNA element(s) is or are not directly linked to the CRE.--
- 15.(amended) Process according to claim 1 wherein the other DNA element(s) is (are) endogenous to said cell.-
-
- 16.(amended) Process according to claim 1 wherein the other DNA element(s) is (are) heterologous to said cell.--
- 20.(amended) Process according to claim 1 wherein the sequence-specific DNA binding compound binds to the DNA minor groove.--

Ulrich Laemmli
Serial No.: Not Yet Known
Filed: Herewith
Page 3

--21.(amended) Process according to claim 1 wherein the
sequence-specific DNA binding compound is cell-
permeable.--

REMARKS

The subject application claims the priority of U.S. Provisional
Application No. 60/213,931, filed June 26, 2000.

By this Amendment, applicants have canceled claims 40-76 without
prejudice to applicants' right to pursue the subject matter of
these claims in a subsequent application and amended claims 9,
11, 15, 16, 20 and 21. Accordingly, claims 1-39 are currently
pending and under examination.

Applicants maintain that amended claims 1-39 raise no issue of
new matter. Accordingly, applicants respectfully request that
the Amendment be entered. An annotated version of amended claims
showing all changes relative to the previous version of that
claim is attached hereto as **Exhibit A**.

Applicants have added the paragraph recited hereinabove to update
the continuing data of the present application.

If a telephone interview would be of assistance in advancing
prosecution of the subject application, applicants' undersigned
attorney invites the Examiner to telephone at the number provided
below.

Ulrich Laemmli
Serial No.: Not Yet Known
Filed: Herewith
Page 4

No fee, other than the enclosed fee of \$715.00 for filing the subject application, is deemed necessary in connection with the filing of this Preliminary Amendment. However, if any additional fee is required, authorization is hereby given to charge the amount of any such additional fee to Deposit Account No. 03-3125.

Respectfully submitted,



John P. White
Registration No. 28,678
Jane M. Love
Registration No. 42,812
Attorneys for Applicants
Cooper & Dunham LLP
1185 Avenue of the Americas
New York, New York 10036
(212) 278-0400

Ulrich Laemmli
Serial No.: Not Yet Known
Filed: Herewith
Page 1

Exhibit A - An annotated version of amended claims showing all changes relative to the previous version of that claim:

- 9.(amended) Process according to claim 1, [2 or 3] wherein the CRE is cis-acting with respect to said other DNA element(s), in either a local or long-range manner.--
- 11.(amended) Process according to [any one of claims] claim 1 [to 4] wherein the CRE is trans-acting in that the other DNA element(s) is or are not directly linked to the CRE.--
- 15.(amended) Process according to [any one of claims] claim 1 [to 14] wherein the other DNA element(s) is (are) endogenous to said cell.--
- 16.(amended) Process according to [any one of claims] claim 1 [to 14] wherein the other DNA element(s) is (are) heterologous to said cell.--
- 20.(amended) Process according to [any one of claims] claim 1 [to 19,] wherein the sequence-specific DNA binding compound binds to the DNA minor groove.--
- 21.(amended) Process according to [any one of claims] claim 1 [to 20] wherein the sequence-specific DNA binding compound is cell-permeable.--